Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|REGN||Regeneron Pharmaceuticals, Inc.||0.35%||463.19||2.7%||$534.62m|
|GILD||Gilead Sciences, Inc.||0.20%||64.75||1.0%||$502.19m|
|VRTX||Vertex Pharmaceuticals, Inc.||0.76%||213.58||1.9%||$461.68m|
|ALXN||Alexion Pharmaceuticals, Inc.||-0.03%||150.06||2.0%||$329.21m|
|BNGO||BioNano Genomics, Inc.||8.67%||7.77||0.0%||$322.31m|
|CRSP||CRISPR Therapeutics AG||-0.90%||113.62||0.6%||$321.43m|
|EXAS||EXACT Sciences Corp.||-4.17%||116.57||18.4%||$244.18m|
|PACB||Pacific Biosciences of California, Inc.||-6.49%||27.37||7.2%||$176.05m|
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170, and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.